Back to discover
Drug

Diclofenac

Established medicine
ClassCyclooxygenase inhibitorResearchOngoing clinical research
Also known as Aleve Arthritis Pain, Arthrotec, Cambia, Cataflam+18 more

Aleve Arthritis Pain, Arthrotec, Cambia, Cataflam, Diclofenac acid, Dyloject, Flector, Licart, Lofena, Pennsaid, Solaraze, Surpass Anti-Inflammatory, Trifena, Voltaren, Xiclo, Zipsor, Zorvolex, Diclofenaco, 2-((2,6-dichlorophenyl)amino)benzeneacetic acid, Diclofenac Potassium, Diclofenac Sodium, Diclofenacum.

11
Active clinical trials
2
Protein targets
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Diclofenac Did Not Reduce Chemo-Induced Hand-Foot Syndrome

Industry2026-09-02Medscape Medical News

Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Diclofenac
Aliases & brands
Aleve Arthritis PainArthrotecCambiaCataflamDiclofenac acidDylojectFlectorLicartLofenaPennsaidSolarazeSurpass Anti-InflammatoryTrifenaVoltarenXicloZipsorZorvolexDiclofenaco2-((2,6-dichlorophenyl)amino)benzeneacetic acidDiclofenac PotassiumDiclofenac SodiumDiclofenacum
RxNorm CUI
3355
ChEMBL ID
CHEMBL139
ATC codes
M01AB55S01BC03D11AX18M01AB05M02AA15
UNII
144O8QL0L1
Primary mechanism
Cyclooxygenase inhibitor
Regulatory jurisdictions
mhra

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

INHIBITORCyclooxygenase inhibitor
INHIBITORCyclooxygenase inhibitor

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
2
mhraMedicines and Healthcare products Regulatory Agency· 2 events
2014-12-11Safety communicationSafety
Drug Safety Update: Diclofenac: public consultation on availability as a pharmacy medicine
Evidence ↗
2014-12-11Safety communicationSafety
Drug Safety Update: Diclofenac: new contraindications and warnings
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

167 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
167
registered trials across all phases
LATEST COMPLETION 2026
11
Active studies
8
Recruiting
126
Late-stage (III+)
115
Completed
41
Discontinued
PHASE DISTRIBUTIONn = 167
Early Phase 14Phase 118Phase 1 / 23Phase 216Phase 2 / 38Phase 327Phase 455Phase N / A36

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.